Join us on November 6-7, 2019 for the 7th Annual International C. diff. Conference and Health EXPO at the DoubleTree by Hilton St. Louis – Westport, MO, USA. Clinical professionals will gather for a two-day conference presenting up-to-date data to expand on the existing knowledge and discuss the urgency focused on, yet not limited to, a Clostridium difficile infection (CDI) –—Prevention, Treatments, Research, Environmental Safety, Clinical trials and studies. There will also be presentations focused on gut Microbiome research, Infection Prevention, Fecal Microbiota Restoration and Transplants. There will be a Panel Of C. diff. Infection Survivors, Antibiotic Stewardship, Presentations, Poster Presentations, Environmental Safety Science, Diagnostics, Treatments and a Healthcare EXPO component. Early Bird Registration is now open.
To review the Clostridium difficile (C.difficile, C.diff) Guidelines for Adults and Children 2017 Update by Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) — Published February 2018
Clostridium difficile is gram-positive, anaerobic, and a spore, rod/spindle-shape,
a common bacterium of the human intestine
in 2 – 5%. C diff. becomes a serious gastrointestinal infection when individuals have been exposed to antibiotic therapy, and/or have experienced a long-term hospitalization, and/or have had an extended stay in a long-term care facility. However; the risk of acquiring a C diff. infection (CDI) has increased as it is in the community and found in outpatient settings. There are significant risk factors in patients who are immunosuppressant, individuals who have been on antibiotic therapy, and the elderly population.
A C. diff. infection (CDI) is an individual infection and no two individuals will present with the same initial symptoms except for the common denominator of unformed, liquid diarrhea and with more than three times within 24 hours before seeking a stool test to confirm the diagnosis. Each individual will have different courses of treatment and the infection may resolve quickly or there may be episodes of recurrent C.difficile which will require additional courses of treatment. Physicians (Primary Care, Gastroenterologist, Infectious Disease) will determine the course of treatment based on the patient’s age, if there are additional illnesses to consider, and discuss treatments with patients to develop a plan of care.
How do Antibiotics cause C diff.? The antibiotics cause a disruption in the normal intestinal flora which leads to an over growth of C difficile bacteria in the colon. Leading antibiotics are known to disrupt the normal intestinal flora.
As far back as November 2012 the CDC started sharing a public announcement regarding antibiotic use: Colds and many ear and sinus infections are caused by viruses, not bacteria. Taking antibiotics to treat a “virus” can make those drugs less effective when you and your family really need them. Limiting the usage of antibiotics will also help limit new cases of CDI.
*Always discuss the symptoms and medications with the treating Physician/Healthcare Provider.
Contact Us Today —
Healthcare Providers, and Triage Nurses are available to speak with
Monday through Friday 9:00 a.m. ET – 5:00 p.m. ET
to learn more about C. diff. Prevention, Diagnosis Symptoms and Transmission Treatments, Environmental Safety and Support Worldwide.
Sarah Mische, PhD discusses the Who, What, and Why of Clinical Trials; Preventing and Treating C.diff. Infections LISTEN TODAY
U.S. Hot-Line 1-844-FOR-CDIF
U.S. Main Number: +1 – (727) – 205-3922
Previous studies indicate that C. difficile has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone. The new study found that 1 out of every 5 patients with a healthcare-associated C. difficile infection experienced a recurrence of the infection and 1 out of every 9 patients aged 65 or older with a healthcare-associated
C. difficile infection died within 30 days of diagnosis.** (1)
The epidemiology of C. diff. infections in the UK:
The height of the epidemic of C. diff. infections in the UK was towards the end of the last decade. There are comprehensive UK data on CDI because of a mandatory reporting system that was introduced over 10 years ago; in England there were ~60 000 cases in 2007-08, with large, hospital based outbreaks, some of which led to multiple official reviews of healthcare practice. Major government-led public health campaigns followed, which included the use of targets for every NHS hospital, financial penalties if targets were missed, and (in 2012) standardized testing for CDI across the NHS. These interventions led to an 80% reduction in CDI rates and in CDI associated mortality; in England there
were ~14 000 cases in 2013-14. There was a small rise in CDI’s (~6% in 2014-15), which is unexplained. CDI remains a key performance management condition in the NHS, and so low rates are considered as a marker of high quality healthcare. (2)
There is validation enough for the C Diff Foundation to continue its’ dedication in lowering morbidity and mortality rates through continued education, advocating, and sharing the C Diff Foundation mission in raising C. diff. awareness with healthcare professionals, healthcare students, healthcare facilities, patients, families, and communities – working towards a shared goal ~ To witness a reduction of newly diagnosed C. diff. cases on a global level — by 2030.
The C Diff Foundation works closely within the healthcare industry, from villages to cities in thirty-eight countries with patients, and in many industries addressing the problems and discussing solutions focused on C. difficile, a common healthcare-associated infection (HAI). “International Raising C.diff. Awareness” takes place through Summits, Symposiums, Workshops, and Annual Conferences each year. The first annual “International Raising C Diff Awareness” Conference was held in November 2013 and brought together some of the best minds in epidemiology and healthcare with new ideas regarding the challenges the world is facing in C.diff. prevention, treatments, and environmental safety. By and through presenting specific, scientific data to meet C. diff. challenges, encouraging healthcare professionals, healthcare organizations, and pharmaceutical organizations to share the
information and providing scientific data being utilized to implement C. diff. solutions.
“Our Foundation is without borders as our outreach expands over horizons dedicated in our mission; Educating and advocating for C. difficile infection prevention, treatments, clinical trials, and environmental safety worldwide to end the suffering from this infection and help save lives.” states
Nancy C. Caralla, Founding President, Executive Director
(2) Dr. Mark Wilcox, MD, FRCPath, Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology at the Leeds Teaching Hospitals (LTHT), Professor of Medical Microbiology at the University of Leeds at their Institute of Biomedical and Clinical Sciences, and is the lead on Clostridium difficile for Public Health England in the UK, C Diff Foundation: Chairperson, Medical Advisory Board.
JOIN US and Share Our Mission To Save Lives Worldwide!
* If you are, or you know someone who is, experiencing
symptoms of a C. difficile infection, please contact a Physician and seek medical attention immediately.
*Please Read Disclaimer Thank you. *
C Diff Foundation © 2019 All Rights Reserved